The extra part matters
CJC-1295 copies a natural signal that tells the pituitary, a small gland at the base of the brain, to release growth hormone. One form has an extra part called DAC. It attaches to albumin, a common blood protein, and helps the compound stay in circulation.
In a small study in healthy adults, that long-acting form had a half-life of roughly a week. Growth hormone and IGF-1, another growth signal, stayed raised for days. Half-life means the time for the compound's blood concentration to fall by half.
The FDA review treats DAC and no DAC as different ingredients. It found no human study of the form without DAC. So the week-long figure stays with the form studied. That missing number is worth leaving missing.
What changed for the people?
Another small study found that growth hormone still rose and fell in pulses. In other words, the higher level didn't remove every natural rise and fall. Interesting, yes. A health benefit on its own, no.
The small published human studies didn't establish better sleep, muscle growth, fat loss or slower ageing. They watched hormones. If those everyday benefits are what brought you here, that's the gap to keep in view.
The safety questions stay open
CJC-1295 has no FDA-approved medical use. The FDA review describes serious reactions involving a faster heartbeat and widened blood vessels. Flushing or low blood pressure can go with that. It also raises immune concerns and flags possible blood sugar and fluid problems by comparison with growth-hormone medicines. For CJC-1295, safety over years is still an unanswered question. A short study can't settle what repeated exposure would mean over years.
CJC-1295 appears under withdrawn nominations on the FDA safety page, marked current April 22, 2026. That means the request to consider it was taken back. It isn't FDA clearance or approval for compounding; the safety concerns are still listed.
I come back to two questions: which form, and which result? The duration comparison uses that same habit across all four topics.